Tirzepatide
Mounjaro, Zepbound, LY3298176
A dual GLP-1 and GIP receptor agonist used for type 2 diabetes and obesity, enhancing insulin secretion, suppressing glucagon, and promoting weight loss.
Active Not Recruiting
PHASE3
NCT06588296
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE2
NCT06643728
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT06075667
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE4
NCT06635057
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT04255433
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE4
NCT05433584
A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Not Yet Recruiting
PHASE2
NCT07078838
Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer
UNC Lineberger Comprehensive Cancer Center
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE2
NCT03311724
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Not Yet Recruiting
NA
NCT07176663
Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure
Shahid Beheshti University of Medical Sciences
INTERVENTIONAL
Updated Dec 15, 2025
Not Yet Recruiting
PHASE2
NCT06737042
Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants
Gan and Lee Pharmaceuticals, USA
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE1, PHASE2
NCT07000955
Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity
Innovent Biologics (Suzhou) Co. Ltd.
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT06534411
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
Novo Nordisk A/S
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT05556512
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
NA
NCT06734312
MAINTAIN (Mucosal AblatIoN Therapy After INcretins)
Dr. Christopher McGowan
INTERVENTIONAL
Updated Dec 15, 2025
Not Yet Recruiting
PHASE4
NCT06657209
Normal-weight Diabetes: Adipocyte-directed Therapy with Pioglitazone or Tirzepatide
Stanford University
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
NA
NCT06431308
Nutritional Therapy to Incretin-based Anti-obesity Medications in the Management of Gastrointestinal Adverse Events
Ariel University
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT04657003
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE2
NCT07128082
The Long COVID Treatment Trial
Scripps Translational Science Institute
INTERVENTIONAL
Updated Dec 15, 2025
Not Yet Recruiting
PHASE2
NCT06820281
Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes
Garvan Institute of Medical Research
INTERVENTIONAL
Updated Dec 15, 2025
Not Yet Recruiting
NCT07156331
Research on Effects of Drugs on Body Composition and Function With Imaging in Diabetes
Kristin Clemens
OBSERVATIONAL
Updated Dec 15, 2025